

RAPID COMMUNICATION

Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood

By Wanda Piacibello, Fiorella Sanavio, Lucia Garetto, Antonella Severino, Daniela Bergandi, Jessica Ferrario, Franca Fagioli, Massimo Berger, and Massimo Aglietta

The use of umbilical cord blood as a source of marrow repopulating cells for the treatment of pediatric malignancies has been established. Given the general availability, the ease of procurement, and progenitor content, cord blood is an attractive alternative to bone marrow or growth factor mobilized peripheral blood cells as a source of transplantable hematopoietic tissue. However, there is a major potential limitation to the widespread use of cord blood as a source of hematopoietic stem cells for marrow replacement and gene therapy. There may be enough hematopoietic stem cells to reconstitute children, but the ability to engraft an adult might require *ex vivo* manipulations. We describe an *in vitro* system in which the growth of cord blood CD34⁺ cells is sustained and greatly expanded for more than 6 months by the simple combination of two hematopoietic growth factors. Progenitors and cells belonging to all hematopoietic lineages are continuously and increasingly gener-

ated (the number of colony-forming unit–granulocyte-macrophage [CFU-GM] present at the end of 6 months of culture are well over 2,000,000-fold the CFU-GM present at the beginning of the culture). Very primitive hematopoietic progenitors, including long-term culture-initiating cells (LTC-ICs) and blast cell colony-forming units, are also greatly expanded (after 20 weeks of liquid culture, LTC-IC number is over 200,000-fold the initial number). The extremely prolonged maintenance and the massive expansion of these progenitors, which share many similarities with murine long-term repopulating cells, suggest that extensive renewal and little differentiation take place. This system might prove useful in diverse clinical settings involving treatment of grown-up children and adults with transplantation of normal or genetically manipulated hematopoietic stem cells.
© 1997 by The American Society of Hematology.

HEMATOPOIETIC tissues contain a small population of primitive, totipotent stem cells capable of self-renewal and of generating committed progenitors of the different myeloid and lymphoid compartments.¹⁻⁴ In the semisolid assays, hematopoietic progenitors in the presence of specific growth factors proliferate and differentiate to give origin to mature cells.⁵ In this system, depending on the combination of growth factors, different classes of multipotent committed progenitors (colony-forming units–granulocyte-macrophage [CFU-GM], burst-forming units-erythroid [BFU-E], and colony-forming units-megakaryocyte [CFU-Mk]) with a high differentiation but a negligible self-renewal capacity are identified.¹⁻⁶

Several culture systems to identify early progenitor/stem cells have been described. In the human system, long-term

culture-initiating cell assay (LTC-IC), which detects cells that can generate myeloid clonogenic cells (colony-forming cells [CFCs]) in long-term cultures for a minimum of 5 weeks, appears to be useful in this regard.⁷ Indeed, human LTC-ICs share a number of features with *in vivo* murine long-term repopulating cells.⁸ A number of other assays have been advanced as potentially having some correlations with long-term murine repopulating cells. These include assays for cobblestone areas colony-forming cells (CAFC),⁹ high proliferative potential colony-forming cells (HPP-CFC),¹⁰ mixed colony-forming units granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM),¹¹ and blast cell colony-forming units (CFU-BI).^{12,13} The development of assays suitable for the detection of human stem cells and their distinction from other hematopoietic cells with more restricted proliferative and differentiation potentials, therefore, has represented so far an important task. Many attempts to identify culture conditions able to support a prolonged and significant expansion of primitive stem cells have been disappointing, despite considerable success with mature committed progenitors. Indeed, although committed progenitor production can be quite impressive, its sharp decline after some weeks suggests that differentiation and not self-renewal predominates.^{14,15} These systems can, therefore, be very useful to expand the committed progenitor population and hopefully to shorten the early phase of cytopenia that follows bone marrow^{16,17} or cord blood¹⁸⁻²⁰ transplantation.

However, their usefulness appears more uncertain in those situations, such as cord blood (CB) transplantation, in which the limited number of stem cells seems to question its feasibility in grown-up children and adults and when a consistent period of pancytopenia is frequent before graft taking.²¹

We describe here a stroma-free cell culture system in which the combined use of FLT3 ligand (FL)²²⁻²⁴ and thrombopoietin (TPO)²⁵⁻²⁹ proved able to maintain for more than 6 months an inexhaustible production of committed hematopoietic progenitors belonging to all hematopoietic lineages. The extremely prolonged maintenance and massive expansion

From the Department of Biomedical Sciences and Human Oncology, Clinical Section, Torino Medical School, University of Torino, Torino, Italy; the Torino Medical School, University of Torino, Hematology/Oncology, Ospedale Mauriziano, Torino, Italy; the Institute for Cancer Research and Treatment (IRCC), Candiolo, Italy; and the Department of Pediatrics, Torino, Italy.

Submitted December 9, 1996; accepted January 27, 1997.

Support for this work was provided by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC; Milan, Italy) and Consiglio Nazionale delle Ricerche (CNR; Rome, Italy) to special project ACRO (Grant No. 01062.PF399) to M.A. and from the Ministero dell'Università e della Ricerca Scientifica e Tecnologica to W.P. and to M.A. L.G. and A.S. are recipients of the "G. Ghicotti Foundation," Ses. Piemonte grants.

Address reprint requests to Wanda Piacibello, MD, Clinica Medica I, Department of Biomedical Sciences and Human Oncology, Via Genova 3, 10126 Torino, Italy.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology.
0006-4971/97/8908-0054\$3.00/0

sion of hematopoietic progenitors (including LTC-IC and CFU-BI) suggest that extensive renewal, with a limited differentiation, take place. This system might prove very useful to expand primitive hematopoietic progenitor/stem cells and to widen the feasibility of cord blood transplantation.

MATERIALS AND METHODS

Cell Sources

Bone marrow (BM) was obtained by aspiration from the posterior iliac crest of fully informed hematologically normal donors. Umbilical cord blood (CB) was obtained at the end of full-term deliveries, after clamping and cutting of the cord by drainage of blood into sterile collection tubes containing the anticoagulant citrate-phosphate dextrose.

CD34⁺ Cell Purification

Mononuclear cells (MNC) were isolated from CB using Ficoll Hypaque (density, 1077; Nyegaard, Oslo, Norway) density centrifugation. Cells were subjected to two cycles of plastic adherence (60 minutes each); they were then washed with Hanks' Balanced Salt Solution (GIBCO BRL, Grand Island, NY).

The CD34⁺ MNC fraction was isolated with superparamagnetic microbeads selection using high-gradient magnetic field and mini-MACS columns (Miltenyi Biotech, Glodbach, Germany).

The efficiency of the purification was verified by flow cytometry counterstaining with a CD34-phycoerythrin (PE; HPCA-2; Becton Dickinson, Mountain View, CA) antibody. In the cell fraction containing purified cells, the percentage of CD34⁺ cells ranged from 90% to 98%.

Recombinant Human Cytokines

The following recombinant purified human cytokines were used in these studies: recombinant human (rh) stem cell factor or c-kit ligand (rhKL) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) were from Genzyme (Cambridge, MA); recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), recombinant human interleukin-6 (rhIL-6), and rhIL-3 were from Sandoz AG (Basel, Switzerland); recombinant human erythropoietin (rhEPO; EPREX) was from Cilag (Milan, Italy); recombinant human FLT3-ligand (rhFL) was obtained from SD Lyman (Immunex Corp, Seattle, WA); rhTPO was obtained from D.C. Foster (Zymogenetics, Seattle, WA); rhIL-7 and rhIL-12 were from R&D Systems Inc (Minneapolis, MN).

Progenitor Assays

LTC-ICs. LTC-ICs were performed as follows. BM stroma was produced by culturing 10⁷ fresh BM MNC in a T₂₅ flask for at least 2 weeks in 5 mL stromal medium (12.5% horse serum [HS] and 12.5% fetal calf serum [FCS]; both from Hyclone [Logan, UT]), Iscove's modified Dulbecco's medium (IMDM; GIBCO BRL), 2-mercaptoethanol (Sigma, St Louis, MO), 10⁻⁶ mol/L hydrocortisone (Sigma), and penicillin/streptomycin. One or 2 days before cocultures, BM stroma was irradiated with 15 Gy and plated at 7 × 10³/cm² in 24-well plates to form preestablished stromal layers for the long-term cultures. Limiting dilutions (1 to 1,000 CD34⁺ CB cells) and equivalent aliquots (ie, limiting dilutions) of the cells grown in long-term stroma-free cultures after 2 to 20 weeks were seeded on top of the irradiated BM stroma in culture medium containing IMDM, 12.5% HS, 12.5% FCS, 2-mercaptoethanol, and 10⁻⁶ mol/L hydrocortisone for 5 weeks at 33°C with weekly changes of half the medium. At the end of the 5-week LTC-IC assay period, nonadherent cells were removed from the cultures, combined with the corresponding trypsinized adherent cells, washed, and assayed for

cells colony forming units (CFU-Cs) in methylcellulose medium containing 1.3% methylcellulose (Fluka Chemika Biochemika, Buchs, Switzerland), 30% FCS, EPO (3 U/mL), IL-3 (20 ng/mL), G-CSF (20 ng/mL), GM-CSF (20 ng/mL), and KL (50 ng/mL). These cultures were incubated at 37°C and colonies were scored 2 to 3 weeks later. LTC-IC enumeration was based on the number of CFU-C scored in the limiting dilution assays (LDA).

Stroma-free long-term cultures. Stroma-free long-term cultures were performed as follows. Two to ten thousand CD34⁺ CB cells were cultured in quadruplicate flat-bottomed 24-well plates in 1 mL of IMDM supplemented with 10% FCS and the following cytokines: IL-3 (10 ng/mL), IL-6 (10 ng/mL), KL (50 ng/mL), FL (50 ng/mL), and TPO (10 U/mL), which were added, alone or in a combination of two or more factors, to each series of microwells twice a week. The wells were grown at 37°C.

At initiation of the culture, the number of CFU-GM present in 1 mL of a single well was determined by agar culture,³⁰ the number of CFU-Mk by plasma-clot technique,³¹ and the number of BFU-E and CFU-GEMM by methylcellulose assay.¹¹ All the assays were performed in quadruplicate.

Every week all the wells were demidepopulated by removal of one half the culture volume, which was replaced with fresh medium and growth factors. Cells of the harvested media were counted and suitable aliquots of the all suspension were assayed for CFU-GM and CFU-Mk every week and for BFU-E, for CFU-GEMM, for CFU-BI, for LTC-IC, and for immunophenotype analysis every 2 or 3 weeks.

The total number of CFU-GM, CFU-MK, BFU-E, and CFU-GEMM present in each LTC well was determined by using the following equation: CFU-E or BFU-E per milliliter of culture = y (observed CFU-C × 2^{*n*}), where *n* is the number of previous demidepopulations^{31,32} and *y* is the number corresponding to the fraction of 1 mL cell suspension (ie, 1/62 = 15.6 μL and 1/34 = μL) that was plated in semisolid assays.

Clonogenic assays. The clonogenic assays were performed as follows. For CFU-GM, 5 × 10² CD34⁺ CB cells of the initial cell suspension or aliquots of the stroma-free long-term cultures were cultured at 4 plates per point in 3% agar, 15% FCS in IMDM (GIBCO). For CFU-Mk, the same number of cells was cultured in plasma clot assay (4 dishes per point) as previously described.^{31,32} For BFU-E and CFU-GEMM, 5 × 10² CD34⁺ CB cells/dish in at least 4 plates per point were cultured in 1.3% methylcellulose (Fluka), 30% FCS in IMDM at 37°C in a humidified atmosphere at 5% CO₂ in air. Colony scoring was performed on day 12 for CFU-MK (at the immunofluorescent microscope after staining with a fluorescein isothiocyanate [FITC]-conjugated MoAb recognizing GPIIb/IIIa) and on day 14 for CFU-GM, BFU-E, and CFU-GEMM. Several growth factors were added at optimum concentrations to sustain the formation of BFU-E and CFU-GEMM: IL-3 (20 ng/mL), GM-CSF (10 ng/mL), Epo (3 U/mL), and KL (50 ng/mL). For CFU-GM, G-CSF (20 ng/mL), GM-CSF (20 ng/mL), IL-3 (20 ng/mL), and KL (50 ng/mL) were added. For CFU-MK, IL-3 (5 ng/mL) was added.

CFU-BI. Blast cell colony assay was performed according to the method described by Leary and Ogawa¹³ by plating 1 × 10³ CD34⁺ CB cells of the initial purified population. IL-3 (10 ng/mL) and IL-6 (10 ng/mL) were added on day 14.

Colonies were scored after 7 to 10 days of incubation at 37°C. When identified, blast cell colonies containing 25 or more cells were replated in secondary cultures for confirmation of their ability to form secondary colonies. For this purpose, blast cell colonies were individually plucked from the culture and suspended in 100 μL IMDM. The samples were gently pipetted to obtain a single cell suspension and then added to 0.9 mL of methylcellulose medium containing 30% FCS, 1% deionized bovine serum albumin (Sigma), 3 U EPO, 20 ng/mL IL-3, 20 ng/mL GM-CSF, 20 ng/mL G-CSF,

and 50 ng/mL KL. Cultures were incubated at 37°C for 14 additional days and all the colonies were enumerated. Smears were prepared using a cytospin for morphologic examinations.

Every 2 to 3 weeks aliquots of the harvested liquid cultures were assayed for CFU-BI. Secondary replating was performed on at least 20 colonies, as described above.

Immunophenotyping by flow cytometry. After purification, aliquots of CD34⁺ CB cells were incubated with mouse IgG (Fluka) to block nonspecific binding to Fc receptor and then stained with a panel of monoclonal antibodies (FITC- or PE-conjugated CD34, CD38, CD33, CD14, CD2, CD19, and CD41 [all from Becton Dickinson] and antiglycophorin [Dakopatts, Glostrup Denmark]). FITC- and PE-conjugated mouse isotype control antibodies were used for each culture.

Every 2 to 3 weeks aliquots of cultured cells were counted, washed, and then subjected to the same procedure. The only difference was that cells were also incubated with propidium iodide (1 mg/mL) to analyze only viable cells.

Flow cytometric analysis was performed using a FACScan cytometer (Becton Dickinson). At least 10,000 events were acquired for each analysis.

RESULTS

In an effort to induce the long-term proliferation and, possibly, the amplification of primitive hematopoietic progenitors contained in CD34⁺ CB cells, we set up stroma-free suspension cultures in which a number of cytokines known to be active on more immature hematopoietic progenitors (IL-3 and IL-6)^{14,15,33} in combination with early acting cytokines (kit ligand or stem cell factor [KL]^{14,15,34-36} and FLT3 ligand [FL])^{22-24,37-41} were used. Although cellular proliferation occurred (7,000- to 12,000-fold the input cell number after 8 weeks of culture with IL-3 and KL or IL-3 and FL), by week 10 the total cell population began to decrease and soon disappeared. Accordingly, the output of committed progenitors (CFU-C) after an initial increase (36-fold the input CFU-C after 8 weeks of culture) by week 10 progressively decreased (Fig 1A and B).

The addition of both KL and FL to IL-3 further enhanced cell proliferation and CFU-C output, but, again, without substantial effects on the long-term maintenance of primitive stem cells.

In contrast, KL plus FL, in the absence of IL-3 or in the presence of IL-6, enhanced progenitor cell proliferation to a much greater extent and for a longer time (after 12 to 14 weeks of culture, the cell output was >10,000- to 20,000-fold the input value, and CFU-C output was greater than 200- to 300-fold). However, at week 14, progenitor cell proliferation slowed down and by week 16 disappeared completely (Fig 1A and B).

c-mpl ligand (TPO) is a likely growth factor also for primitive stem cells^{26-29,42-45}; therefore, we sought whether the combination of TPO with another early acting cytokine would support the long-term proliferation and perhaps the renewal of primitive human CB hematopoietic stem cells.

In an attempt to carefully investigate the proliferative events occurring during the long-term cultures, different stages of hematopoiesis were analyzed.

CD34⁺ Cell Proliferation

Highly purified CD34⁺ CB cells were cultured in stroma-free liquid cultures with FL and TPO, alone or combined,

for more than 6 months (Fig 2A). The total cell counts were performed weekly. In the cultures without cytokines, a rapid decrease in cell number was observed during the first 3 weeks and by day 21 no cells were alive. Cultures set up with either TPO or FL alone lasted, respectively, 4 and 10 weeks.

By contrast, in the long-term cultures (LTC) containing the association of FL and TPO, a progressive, steady increase of cell production was seen. After 5 weeks the cell output was greater than 1,000-fold the input number; after 15 weeks, it was greater than 1,000,000-fold and at week 25 the cell output was greater than 50,000,000-fold the input number.

Immunophenotype of Cultured Cells

Cells harvested weekly were assayed by flow cytometry for surface antigen expression using essentially viable cells (Fig 2B). The CD34⁺ cell population, in the presence of FL + TPO kept increasing throughout the LTC period. After 5 weeks, CD34⁺ cells were close to 1,600-fold the initial value; after 20 weeks, they reached 146,000-fold the initial value and kept growing.

Previous studies have shown that CD34⁺ CD38⁻ cells constitute a small population of primitive hematopoietic stem cells enriched for LTC-IC.^{46,47} We thus wanted to see whether this subpopulation persisted during the LTC period. As shown in Fig 2B, the CD34⁺ CD38⁻ subpopulation not only persisted, but underwent a continuous expansion. Indeed, after 5 weeks of culture, it was 300-fold the input value; at week 20, it was greater than 500,000-fold the input number and kept expanding. The complete immunophenotyping of cultured cells showed that the most of the cells produced in LTC belonged to the granulocyte-macrophage, the erythroid, and the megakaryocyte lineages. CD2⁺ and CD19⁺ cells represented only 0.2% and 0.012% of the total cell population.


CFC Content and Amplification in LTCs

To measure the progenitor content of the cell expansion occurring throughout the LTC, semisolid assays for CFU-GM and CFU-Mk were performed weekly and for BFU-E and for CFU-GEMM were performed every 2 to 3 weeks. Figure 2C shows the fold increase, over time, of CFU-GM, CFU-Mk, BFU-E, and CFU-GEMM generated during 6 months of liquid cultures.

After 5 weeks of culture, CFU-GM output was greater than 70-fold and by week 25 was greater than 6,000,000-fold the input value. Besides CFU-GM, during the entire culture period, CFU-Mk, BFU-E, and CFU-GEMM were generated by the expanded cells. Indeed, CFU-Mk generated after 15 weeks of culture were 1,000-fold the number of CFU-Mk present in the inoculum at the beginning of the suspension cultures. After 25 weeks, they were well over 45,000-fold the input number. Similarly, BFU-E and CFU-GEMM were generated during the entire culture period (at week 15, they were, respectively, >9,000- and >850-fold; at week 25, they were >122,000-fold and >27,000-fold the input number, respectively).

In an effort to show that, among the cells growing in the LTC, totipotent stem cells were present, we sought to find

Fig 1. (A) Nonadherent cell expansion from CD34⁺ CB cells. Two thousand CB cells in 1 mL were plated in quadruplicate 24-well plates on day 0. Cells were cultured in stroma-free in LTC medium in the presence of FL, KL, IL-3, and IL-6 alone or combined. Every week half the culture volume was removed from cell culture and the cells were counted. The mean fold increase over cell number plated on day 0 is shown at each time point of LTC. Mean \pm SEM from three separate experiments performed in quadruplicate. (B) CFU-GM expansion from CD34⁺ CB cells in stroma-free LTC. Two thousand CD34⁺ CB cells were plated in quadruplicate 24-well plates in the presence of the factors reported above. The content of CFU-GM of each well was established at the beginning of the LTC by agar assays. Every week all the wells were demidepopulated by removal of one half the culture volume, which was replaced with freshly medium and growth factors. Cells of the harvested media were counted and suitable aliquots of the cell suspension were assayed for CFU-GM in quadruplicate dishes. The results represent the mean \pm SEM of three separate experiments performed in quadruplicate. (\blacktriangle) IL-3 + FL; (\triangle) IL-3 + KL; (\bullet) IL-3 + KL + FL; (\square) IL-6 + FL + KL; (\blacksquare) KL + FL.



out whether T and B cells had been generated. At the beginning of the cultures, the frequency of T and B cells in the CD34⁺ cell population was very low. After several weeks of liquid culture, T and B cells were barely detectable (CD2⁺ and CD19⁺ cells represented, respectively, 0.2% and 0.012%). However, after incubation for an additional 14 days in the presence of IL-7, IL-12, and FL, the percentage of CD2⁺ cells ranged from 24.98% to 33.8% and CD19⁺ cells ranged from 0.78% to 3.75% (Table 1).

LTC-IC Content and Amplification in Suspension Cultures

The frequency of LTC-IC in the initial CD34⁺ CB cells (input value) was 0.6% \pm 0.4%. This was determined by

LDA by plating from 1 to 1,000 CD34⁺ cells onto preestablished irradiated feeder layers from normal BM and then assessing the number of CFC present 5 weeks later.

After 2 weeks of liquid culture, the LTC-IC content, determined by LDA as for input LTC-IC by evaluating the number of CFC generated after 5 additional weeks in the standard BM stroma assay, was found to be 160-fold the input value. After 10 weeks of LTC, the LTC-IC number was 1,000-fold and by week 20 was over 200,000-fold the input value (Table 2).

CFU-BI

Primitive hematopoietic progenitors capable in vitro of producing colonies composed of blast cells (CFU-BI) have




Fig 2. Different stages of hematopoiesis in stroma-free LTC of CD34⁺ cells. (A) Expansion of hematopoietic cells in stroma-free cultures stimulated by TPO (10 U/mL) alone (●), by FL (50 ng/mL) alone (○), and by the combination of TPO (10 U/mL) + FL (50 ng/mL) (■). The starting population was represented by 2×10^3 CD34⁺ CB cells in 1 mL in 24-well plates. Fresh growth factors were added twice a week. Cells were counted weekly from quadruplicate wells and the fold increase was obtained by dividing the number of cells of each well counted each week by the number of the starting population. Represented here is the mean \pm SEM of four different experiments (each performed in quadruplicate). (B) Expansion of the CD34⁺ (■) and the CD34⁺ CD38⁻ (●) cell populations during LTC with FL + TPO. CB CD34⁺ cells were grown as described in Fig 1 for 25 weeks. Every 2 to 3 weeks the cells harvested were stained with FITC- and PE-conjugated anti-CD34 and anti-CD38 MoAb. The total number of each subpopulation was obtained by multiplying the percentage of each subset by the number of cells contained in each well. Results are expressed as the fold increase (compared with the starting subpopulation) and represent the mean \pm SEM of analyses performed on quadruplicate wells in four separate experiments. (□) CD34⁺ cells in LTC grown in the presence of FL alone. (○) CD34⁺ cells in LTC grown in the presence of TPO alone. (C) Production of hematopoietic progenitors in LTC in the presence of FL + TPO. CD34⁺ CB cells were grown for 25 weeks as described in Fig 1. CFU-GM (■), CFU-MK (○), BFU-E (●), and CFU-GEMM (□) were cultured as described in Fig 1. Results represent the fold increase of each class of progenitors present in each well in determined periods of LTC, compared with the number of progenitors of the beginning of the cultures. Mean \pm SEM of four wells per point in four separate experiments.

Table 1. Appearance of CD2⁺ Cells After 12 Weeks of LTC

Experiment No.	% CD2 ⁺ Cells		% CD19 ⁺ Cells	
	Untreated*	+FL + IL-7 + IL-12	Untreated*	+FL + IL-7 + IL-12
1	0.12 ± 0.01	33.8 ± 1.1	0.012 ± 0	1.4 ± 0.3
2	0.24 ± 0.03	42.36 ± 2.3	0.01 ± 0	0.78 ± 0.1
3	0.18 ± 0.08	24.98 ± 2.1	0.02 ± 0	3.75 ± 0.2

* CD34⁺ CB cells (2 × 10³) were grown in stroma-free LTC containing FL + TPO for 12 weeks and then were analyzed for CD2 and CD19 expression (untreated). Analogous replicate samples were incubated for additional 14 to 21 days in the presence of 50 ng/mL FL, 100 U/mL IL-7, and 100 U/mL IL-12. The cells were then harvested and analyzed for CD2 and CD19 expression. The results are the mean ± SEM of analyses performed in triplicate wells.

been described.¹³ These cells possess many features of stem cells in that they are capable of self-renewal and also of commitment towards a number of hematopoietic lineages.

In our hands, at the beginning of long-term suspension cultures, 63% ± 5.4% of the CFU-BI were capable of generating secondary colonies after replating. Each blast colony generated a mean of 5.6 ± 1.2 secondary colonies. During the LTC period, CFU-BI underwent a progressive expansion paralleling with that of other more mature committed progenitors (Table 3). Thus, after 5 weeks of LTC, the CFU-BI colony number was 43-fold the input number and at week 20 reached 305,000-fold the number present in the initial inoculum. In addition, expanded CFU-BI still retained their self-renewal capacity (or, at least, maintained the capacity to differentiate toward multiple lineages). When the blast cell colonies were replated in methylcellulose containing IL-3 + IL-6, new blast cell colonies were generated, which, in turn, were capable of generating tertiary colonies (data not shown).

Analysis of the time course of CFC expansion showed that the generation of CFU-GM did not show an entirely linear progression (Fig 3A and B). Indeed, three to four waves of colony generation were evident at certain time points in all the experiments. The earliest peak was seen around 5 weeks of culture and, since then, a peak was clearly detectable every 4 to 5 weeks. The last peak occurred at week 25 (Fig 3A). Overall, the picture seems to reflect a production of clonogenic precursors from more and more primitive stem cell subpopulations, which are driven into proliferation after progressively longer periods of time. Alternatively, it might also indicate that, during such a long period of liquid culture, self-renewal of primitive stem cells has occurred.

The colonies generated in semisolid assays, in identical culture conditions, and in the presence of identical growth factors, after several months of liquid culture, were much larger (up to 1,000 cells), as if committed progenitors possessed an higher proliferative potential.

DISCUSSION

Our data demonstrate that the simple combination of two hematopoietic growth factors (FL and TPO), in the absence of stromal cells, is capable of sustaining for more than 6

Table 2. LTC-IC Amplification in CD34⁺ CB Cells Cultured in LTC in the Presence of Various Cytokine Combinations

Factors Added	No. of Cells/100 Initial Nucleated Cells																		
	Nonadherent Cells					CFU-C					LTC-IC								
	Start	2 wk	5 wk	10 wk	15 wk	20 wk	Start	2 wk	5 wk	10 wk	15 wk	20 wk	Start	2 wk	5 wk	10 wk	15 wk	20 wk	
Med	100	360	0	0	0	0	13.2	0	0	0	0	0	0	0.6	0	0	0	0	0
FL	100	8,400	97,500	51,000	0	0	13.2	144	847	0	0	0	0	0.6	0.75	0.63	0	0	0
TPO	100	4,800	2,000	0	0	0	13.2	51.2	0	0	0	0	0	0.6	0	0	0	0	0
FL + TPO	100	9,400	197,000	1,025,000	89,700,000	1,074,790,000	13.2	206	2,947	154,091	2,873,468	21,936,205	0.6	96	ND	ND	599	1,975	83,886
KL + FL + TPO	100	25,000	227,000	2,514,000	124,110,000	1,454,895,000	13.2	202	835	58,655	2,714,461	17,469,274	0.6	76.8	ND	ND	ND	ND	31,457
IL-3 + FL + TPO	100	19,400	185,000	128,000	0	0	13.2	157	1,597	0	0	0	0	0.6	0.4	0	0	0	0

Differential ability of FL, TPO, KL, and IL-3, alone or combined, to support different stages of hematopoiesis in long term stroma-free cultures suspension cultures of CD34⁺ CB cells. Cultures were initiated with 2 × 10³ highly purified CD34⁺ CB cells and maintained as described in the Materials and Methods. Results show the mean of three to five experiments performed in duplicate after normalization of each result per 100 cells seeded into each type of culture. The column on the left shows the number of cells generated after progressively longer periods of time in liquid cultures. The central column shows the committed progenitor production in the same liquid cultures. The right-side column shows the generation and expansion of primitive stem cells (identified as LTC-IC).

Table 3. Progressive Expansion of CFU-BI in LTCs

Weeks of LTC	Blast Cell Colonies		
	Fold Increase	% Recloning Efficiency*	No. of Secondary Colonies/ Blast Colony
0	1	63 ± 5.4	5.6 ± 1.2
+3	9.24 ± 0.6	55 ± 2.6	5.2 ± 0.4
+5	43 ± 2.7	ND	ND
+8	421 ± 11	ND	ND
+10	4,200 ± 97	61 ± 3.1	4.3 ± 1.2
+12	5,407 ± 145	ND	ND
+15	28,672 ± 1,200	58 ± 2.3	6 ± 0.8
+18	65,556 ± 2,406	ND	ND
+20	305,420 ± 12,400	53 ± 4.6	6.7 ± 1.2

Ability of FL + TPO to support CFU-BI in LTC. CFU-BI generated by 1,000 CD34⁺ CB cells at the beginning of the LTC (time 0) and secondary colonies after replating (mean ± SEM values from 3 separate experiments). Secondary clones comprised all types of colonies (GM, G, erythroid, burst, and GEMM clones represented the total numbers of colonies, respectively).

* The recloning efficiency is the percentage of colonies that generates secondary colonies upon replating. Results represent the mean ± SEM of three separate experiments.

months both proliferation and renewal of CB primitive stem cells, without any sign of their exhaustion.

The progenitor cells and the cells produced in this system possess both antigenic and growth characteristics of all hematopoietic lineages, including those of T and B cells; thus, the cells assayed during the extended period of LTC are likely to represent primitive stem cells. The progressively higher and higher waves of CFU-C generation that can be identified during the entire period of LTC suggest the presence of numerous populations of primitive, deeply quiescent stem cells, which begin to proliferate only after more and more prolonged periods of time, well after that of the standard LTC-ICs and the extended LTC-ICs (ELTC-ICs).⁴⁸ Consistent with the very prolonged and massive progenitor output, which is still expanding after 5 months of liquid culture (CFU-GM number after 25 weeks of LTC is over 6,000,000-fold the initial number), the LTC-IC number is also in continuous expansion (after 20 weeks it is over 200,000-fold the input number).

It has recently been shown that the CD34⁺ CD38⁻ immunophenotype defines a rare and primitive subpopulation of hematopoietic progenitor cells in BM and CB enriched for LTC-IC.^{46,47} Our starting population was composed of both CD34⁺ CD38⁺ and CD34⁺ CD38⁻ CB cells. It is possible that the early wave of CFU-C production is sustained by the CD34⁺ CD38⁺ population and that the later waves, after 8 to 10 weeks of culture, are generated by the CD34⁺ CD38⁻ subpopulation.

Besides the LTC-ICs, which reflect the presence of primitive, *in vivo* long-term repopulating stem cells, other assays have been used in this study to measure generation and amplification of primitive stem cells. CFU-BI^{12,13} possess many features of stem cells in that they are capable of self-renewal and also commitment toward a number of hematopoietic lineages. In the LTC described here, the population of CFU-BI not only is maintained, but also is greatly expanded. What is more, the expanded population, after several

weeks of liquid culture, still retains its capability to self-renew and to generate colonies of cells belonging to granulocyte-macrophage, erythroid, and megakaryocyte lineages and colonies of blast cells, which, in turn are capable of tertiary replating. This represents an additional proof of the capability of this culture system to sustain and expand also primitive progenitors.

So far, LTC systems capable to support human hematopoiesis for extended periods of time, without exhaustion of primitive stem cells, are all dependent on the presence of marrow stromal feeder layers.^{14,15,40,46,48} At the present time, the molecular mechanisms that mediate stromal cell-based stimulation of LTC-IC proliferation and differentiation are not known. Previous studies showing the ability of immortalized murine fibroblasts to substitute for human marrow feeder layers in human LTC-IC assays, including fibroblasts genetically unable to produce KL, have suggested that novel growth factors may be involved.⁴⁹ The possibility that FLT3 ligand may play a role in this regard has emerged.²²⁻²⁴ Moreover, it has been recently reported that incubation of single CD34⁺ CD38⁻ BM cells in medium supplemented with FL, KL, IL-3, IL-6, G-CSF, and nerve growth factor resulted in the proliferation of initial cells to produce clones containing LTC-IC. A 50-fold overall expansion in a 3- to 5-week time frame was observed, indicating the ability of that cytokine mixture to stimulate primitive cells.³⁹

The simple combination of the two growth factors used here proved able to maintain for at least 6 months a very large and continuously increasing production of hematopoietic progenitors belonging to all lineages. This extremely prolonged maintenance and the massive expansion of primitive hematopoietic progenitors, including CFU-BI and LTC-IC, suggest that extensive renewal, with little differentiation, takes place.

FLT3 ligand was a likely candidate for supporting primitive hematopoietic stem cell growth²²⁻²⁴; however, in our assay, FL, by itself, was not sufficient to sustain long-term hematopoiesis. Indeed, previous studies showed its ability to act synergistically with more lineage-restricted growth factors and other early acting cytokines, such KL.³⁷⁻⁴¹ In our system, the association of FL with IL-3 or IL-6 resulted in an impressive CFU-GM output that, on the other hand, was not accompanied by maintenance of primitive stem cells.

Also, TPO by itself proved unable to sustain long-term hematopoiesis. Indeed, most studies initially suggested that TPO was a lineage-restricted regulator with little or no activity on nonmegakaryocytic lineages.²⁵⁻²⁹ Nevertheless, in populations of mouse fetal liver enriched for primitive hematopoietic cells, a significant proportion of cells express c-mpl.⁵⁰ Moreover, recent data suggest that, in combination with EPO, TPO may augment growth of erythroid progenitors⁴² and cells of human nonmegakaryocytic leukemias can proliferate in response to TPO.⁵¹ An elevation of the number of CFU-GEMM has also been observed upon TPO administration in monkeys.⁵² Finally, c-mpl-deficient mice displayed reduced total hematopoietic progenitor cell numbers, including multipotential, blast, and committed progenitors of multiple lineages.⁴³

Thus, the simple combination of FL and TPO resulted to be both necessary and sufficient to sustain long-term stem





Fig 3. Time course of CFU-GM expansion from CD34⁺ CB cells. Two thousand CD34⁺ cells were plated on day 0 in duplicate in 24 wells in the presence of FL + TPO. Every week the content of CFU-GM per well was determined. The vertical axis represents the CFU-GM expansion during 25 weeks of LTC. Two independent experiments of four are shown.

cell proliferation and renewal. The clinical applications seem very exciting: transplantation of adults and grown-up children could be extremely facilitated if CB hematopoietic progenitor stem cells can be readily expanded. Moreover, the ability to control and amplify pluripotent stem cell renewal and expansion will provide a major boon to stem cell gene therapeutics and could permit increased levels of stem cell transduction, thus allowing diverse applications of stem cell modification.

ACKNOWLEDGMENT

We thank Stewart D. Lyman (Immunex) for providing FLT3 ligand and Donald C. Foster (Zygenetics) for providing TPO.

REFERENCES

1. Metcalf D, Moore, MAS: Hematopoietic Cells. New York, NY, North Holland, 1971
2. Till JE, McCulloch EA: Hemopoietic stem cell differentiation. *Biochim Biophys Acta* 605:431, 1980
3. Baum CM, Weissmann IL, Tsukamoto AS, Buckle AM, Peault B: Isolation of a candidate human hematopoietic stem cell population. *Proc Natl Acad Sci USA* 89:2804, 1992
4. Berardi AC, Wang A, Levine JD, Lopez P, Scadden DT: Functional isolation and characterization of human hematopoietic stem cells. *Science* 267:104, 1995
5. Broxmeyer HE: Hematopoietic stem cells, in Trubowitz S, Davis E (eds): *The Human Bone Marrow*. Boca Raton, FL, CRC, 1982, p 77
6. Ogawa M: Differentiation and proliferation of hematopoietic stem cells. *Blood* 81:2844, 1993
7. Coulombel L, Eaves AC, Eaves CJ: Enzymatic treatment of long term human marrow cultures reveals the preferential location of primitive hemopoietic progenitors in the adherent layer. *Blood* 62:291, 1983
8. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves C: Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. *Proc Natl Acad Sci USA* 87:3584, 1990
9. Breems DA, Blokland EAW, Neben S, Ploemacher RE: Frequency analysis of human primitive hematopoietic stem cells subsets using a cobblestone area forming cell assay. *Leukemia* 8:1095, 1994
10. Bertonecello I, Bradley TR, Hodgson GS, Dunlop JM: The resolution, enrichment, and organization of normal bone marrow high proliferative potential colony-forming cell subsets on the basis of rhodamine-123 fluorescence. *Exp Hematol* 19:174, 1991
11. Fauser AA, Messner HA: Proliferative state of human pluripotent hemopoietic progenitors (CFU-GEMM) in normal individuals and under regenerative condition after bone marrow transplantation. *Blood* 54:1197, 1979
12. Gordon MY, Dowding CR, Riley GP, Greaves MF: Characterization of stroma-dependent blast colony-forming cells in human marrow. *J Cell Physiol* 130:150, 1987
13. Leary AG, Ogawa M: Blast cell colony assay for umbilical cord blood and adult bone marrow progenitors. *Blood* 69:953, 1987
14. Emerson GE: Ex vivo expansion of hematopoietic precursor, progenitors, and stem cells: The next generation of cellular therapeutics. *Blood* 87:3082, 1996
15. Moore MAS: Expansion of myeloid stem cells in culture. *Semin Hematol* 32:183, 1995
16. Chang J, Morgenstern G, Deakin D, Testa NG, Coutinho L, Scharffe JH, Harrison C, Dexter TH: Reconstitution of hemopoietic system with autologous marrow taken during relapse of acute myeloblastic leukemia and grown in long-term culture. *Lancet* 1:294, 1986
17. Barnett MJ, Eaves CJ, Phillips GL, Kalousek DK, Klingemann HG, Lansdorp PM, Reece DE, Shepherd JD, Shaw GJ, Eaves AC: Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture. *Bone Marrow Transplant* 4:345, 1989
18. Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D, Army M, Thomas L, Boyse EA: Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. *Proc Natl Acad Sci USA* 86:3828, 1989
19. Gluckman E, Broxmeyer HE, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P, Cooper S, English D, Kurtzberg J, Bard J, Boyse EA: Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. *N Engl J Med* 321:1174, 1989
20. Broxmeyer HE, Gluckman E, Auerbach A, Douglas GW, Friedman H, Cooper S, Hangoc G, Kurtzberg J, Bard J, Boyse EA: Human umbilical cord blood: A clinically useful source of transplantable hematopoietic stem/progenitor cells. *Int J Cell Cloning* 8:76, 1990
21. Broxmeyer HE, Hangoc G, Cooper S, Ribeiro RC, Graves V, Yoder NM, Wagner J, Vadhan-Raj S, Benninger L, Rubinstein P: Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. *Proc Natl Acad Sci USA* 89:4109, 1992
22. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FA, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP: Molecular cloning of a ligand for the flt3/flk2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. *Cell* 75:1157, 1993
23. Lyman SD, James L, Johnson L, Brasel K, deVries P, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ: Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. *Blood* 83:2795, 1994
24. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Menon S, Shanafelt A, Muench M, Kelner G, Namikawa R, Rennick D, Roncarolo MG, Zlotnick A, Rosnet O, Dubreuil P, Birnbaum D, Lee F: Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of hemopoietic stem cells and is encoded by variant RNAs. *Nature* 368:643, 1994
25. De Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, Oles KJ, Hultgren B, Solberg LA Jr, Goeddel DV, Eaton DL: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. *Nature* 369:533, 1994
26. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, Chang MS, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu RY, Parker VP, Suggs S, Skrine JD, Merewether LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, Choi E, Pangelinan M, Sun Y, Mar V, McNinch J, Simonet L, Jacobsen F, Xie C, Shutter J, Chute H, Basu R, Selander L, Trollinger D, Sieu L, Padilla D, Trail G, Elliot G, Izumi R, Covey T, Crouse J, Garcia A, Xu W, Del Castillo J, Biron J, Cole S, Hu MCT, Pacifici R, Ponting I, Saris C, Wen D, Yung YP, Lin H, Bosselman RA: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. *Cell* 77:1117, 1994
27. Lok S, Kaushansky K, Holly R.D, Kuijper JM, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, O'Hara PJ, Hagen FS, Roth GJ, Foster DC: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. *Nature* 369:565, 1994
28. Kuter DJ, Beeler DL, Rosemberg RD: The purification of

- Megapoietin. A physiological regulator of megakaryocyte growth and platelet production. *Proc Natl Acad Sci USA* 91:11104, 1994
29. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. *Blood* 86:419, 1995
30. Piacibello W, Fubini L, Sanavio F, Brizzi MF, Severino A, Garetto L, Stacchini A, Pegoraro L, Aglietta M: Effects of human FLT3 ligand on myeloid leukemia cell growth: Heterogeneity in response and synergy with other hematopoietic growth factors. *Blood* 86:4105, 1995
31. Piacibello W, Garetto L, Sanavio F, Severino A, Fubini L, Stacchini A, Dragonetti G, Aglietta M: The effects of human FLT3 ligand on *in vitro* human megakaryocytopoiesis. *Exp Hematol* 24:340, 1996
32. Aglietta M, Monzeglio C, Sanavio F, Apra F, Morelli S, Stacchini A, Piacibello W, Bussolino F, Bagnara G, Zauli G, Stern AC, Gavosto F: *In vivo* effect of human granulocyte-macrophage colony-stimulating factor on megakaryocytopoiesis. *Blood* 77:1191, 1991
33. Mayani H, Dragowska W, Lansdorp PM: Characterization of functionally distinct subpopulations of CD34⁺ cord blood cells in serum-free long-term cultures supplemented with hematopoietic cytokines. *Blood* 82:2664, 1993
34. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR, Satyagal VN, Tung W, Bosselman RA, Mendiaz EA, Lengley KE: Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat-liver-conditioned medium. *Cell* 63:195, 1990
35. Metcalf D, Nicola NA: Direct proliferative actions of stem cell factor on murine bone marrow cells *in vitro*: Effect of combination with colony-stimulating factors. *Proc Natl Acad Sci USA* 88:6239, 1991
36. Migliaccio G, Migliaccio AR, Druzin ML, Giardina PJV, Zsebo KM, Adamson JW: Long-term generation of colony-forming cells in liquid culture of CD34⁺ cord blood cells in the presence of recombinant human stem cell factor. *Blood* 79:2620, 1992
37. Gabbianelli M, Pelosi E, Montesoro M, Valtieri M, Lucchetti L, Samoggia P, Vitelli L, Barberi T, Testa U, Lyman S, Peschle C: Multi-level effects of flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. *Blood* 86:1661, 1995
38. McKenna HJ, de Vries P, Brasel K, Lyman SD, Williams DE: Effect of flt3 ligand on the *ex vivo* expansion of human CD34⁺ hematopoietic progenitor cells. *Blood* 86:3413, 1995
39. Petzer AL, Hogge DE, Lansdorp PM, Reid DS, Eaves CJ: Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) *in vitro* and their expansion in defined medium. *Proc Natl Acad Sci USA* 93:1470, 1996
40. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM: Flt3 ligand induces proliferation of quiescent human bone marrow CD34⁺ CD38⁻ cells and maintains progenitor cells *in vitro*. *Blood* 87:3563, 1996
41. Namikawa R, Muench MO, de Vries JE, Roncarolo MG: The flk2/flt3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells *in vitro*. *Blood* 87:1881, 1996
42. Kaushansky K, Broudy VC, Grossmann A, Humes J, Lin N, Reng HP, Bailey MC, Papayannopoulou T, Forstrom JW, Sprugel KH: Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. *J Clin Invest* 96:1683, 1995
43. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D: Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl. *Blood* 87:2162, 1996
44. Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, Kaushansky K: The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. *Blood* 87:4998, 1996
45. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M: Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with Steel factor and/or interleukin-3. *Blood* 88:429, 1996
46. Hao QL, Shah AJ, Thiemann FT, Smogorzewska EM, Crooks GM: A functional comparison of CD34⁺CD38⁻ cells in cord blood and bone marrow. *Blood* 86:3745, 1995
47. Randall TD, Lund FE, Howard MC, Weissman IL: Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells. *Blood* 87:4057, 1996
48. Hao QL, Thiemann FT, Petersen D, Smogorzewska EM, Crooks GM: Extended long-term culture reveals a highly quiescent and primitive human hematopoietic progenitor population. *Blood* 88:3306, 1996
49. Sutherland HJ, Hogge DE, Cook D, Eaves CJ: Alternative mechanism with and without steel factor support primitive hematopoiesis. *Blood* 81:1465, 1993
50. Zeigler FC, de Sauvage F, Widmer HR, Keller GA, Donahue C, Schreiber RD, Malloy B, Hass P, Eaton D, Matthews W: *In vitro* megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. *Blood* 84:4045, 1994
51. Matsumura I, Kanakura Y, Kato T, Ikeda H, Ishikawa J, Horikawa Y, Hashimoto K, Moriyama Y, Tsujimura T, Nishiura T, Miyazaki H, Matsuzawa Y: Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. *Blood* 86:703, 1995
52. Farese AM, Hunt P, Grab LB, MacVittie TJ: Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in non human primates after radiation-induced marrow aplasia. *J Clin Invest* 9:2145, 1996